About
The Archive

MinMaxMuscle is a database of research on peptides and performance compounds — organized around the science of muscle growth, fat loss, and recovery.

The site runs on "System over Motivation" — structured data and honest reporting on what the clinical literature actually shows, not hype or vendor claims.

Core Philosophy

"Data-driven optimization. No dogma. Just what works, what doesn't, and the clinical rationale behind it."

Every dossier pulls from primary clinical literature cross-referenced against real-world protocols. This is educational and harm-reduction content — not medical advice.

How We Source Data

Every dossier in this archive is built from primary scientific literature. We do not rely on anonymous forums, vendor marketing, or unsourced anecdote. Below are the authoritative databases and registries this archive draws from.

PubMed / NCBI

The U.S. National Library of Medicine's database of peer-reviewed biomedical literature. Primary source for pharmacokinetic data, receptor binding studies, and human clinical trial results for every compound in this archive.

pubmed.ncbi.nlm.nih.gov

ClinicalTrials.gov

The U.S. National Institutes of Health registry of publicly and privately supported clinical studies. Used to determine current trial phase, enrollment status, primary endpoints, and investigator institutions for each compound.

clinicaltrials.gov

FDA Databases

FDA Orange Book (approved drugs), the FDA 503A/503B bulk drug substance lists (compounding categories), and FDA drug safety communications. These are the authoritative sources for all regulatory status designations used in this archive.

fda.gov

DrugBank / ChEMBL

Curated pharmacological databases maintained by research institutions. Primary sources for molecular weights, amino acid sequences, half-lives, and mechanism-of-action data cited in each compound's molecular data section.

drugbank.com · ebi.ac.uk/chembl

Clinical Editorial Policy

01. Source Hierarchy

We prioritize data from peer-reviewed journals (PubMed/NCBI), clinical trial registries (ClinicalTrials.gov), and established pharmacological databases. Anecdotal data is only included when clearly marked and supported by biochemical rationale.

02. Cross-Reference Standard

Molecular weights, amino acid sequences, and half-lives are verified against at least two independent authoritative sources — typically PubMed and DrugBank or ChEMBL — before a dossier is published. Discrepancies are flagged and resolved against the primary literature.

03. Transparency & Bias

MinMaxMuscle is an independent archive. We maintain zero financial relationships with research chemical suppliers to ensure that our clinical analysis remains unbiased and objective.

Research Status Explained

Every compound in the MinMaxMuscle library carries a regulatory status label. Here is exactly what each designation means.

FDA Approved

The compound has been reviewed and approved by the U.S. Food and Drug Administration for at least one specific medical indication. Approval means safety and efficacy have been established in large-scale clinical trials for the approved use. Examples: Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro/Zepbound), Tesamorelin (Egrifta).

Phase 3 Clinical

The compound is in large-scale Phase III clinical trials — the final stage before potential FDA approval. Phase 3 trials involve thousands of participants and directly compare the compound against existing treatments or placebo. These compounds have already demonstrated safety and preliminary efficacy in earlier phases. Examples: Retatrutide, Cagrilintide, Thymosin Beta-4.

Phase 2 Clinical

The compound is in Phase II trials, which test efficacy and optimal dosing in a targeted patient population (typically 100–300 participants). Phase 2 compounds have cleared initial safety evaluations but have not yet undergone the large confirmatory trials required for approval. Examples: SS-31, ARA-290, Kisspeptin, Amycretin.

FDA Category 2

The compound is classified by the FDA as a Category 2 substance, meaning it appears on the FDA's list of drugs that raise significant safety concerns when used in compounding. These compounds have not been approved for general use and cannot be legally compounded by licensed pharmacies for human use in the United States. They exist in a legal grey area and are sold as research chemicals. Examples: BPC-157 (compounded), Ipamorelin, CJC-1295, Semax, Selank.

Research Only

The compound has no current FDA approval and is not in active large-scale clinical trials for human use. It is available solely as a research chemical for laboratory purposes. Human data is limited primarily to case reports, small observational studies, or animal model research. These compounds have the least established safety profiles. Examples: BPC-157 (oral), IGF-1 LR3, MOTS-c, Epitalon, 5-Amino-1MQ.

Cosmetic / FDA Cat 2

The compound is legally sold and used in over-the-counter cosmetic products (e.g., serums, creams) where it does not require FDA drug approval. However, when used at higher concentrations or administered systemically (e.g., injected), it falls into FDA Category 2 territory and is not approved for medical use. Example: GHK-Cu (copper peptide) is commonly found in skincare but injected forms are research-only.

Clinical Data

Every compound is indexed with molecular weights, half-lives, and phase trial summaries.

Zero Dogma

We analyze high-performance protocols without bias, focusing strictly on physiological outcomes.

Harm Reduction

Educational resources designed to minimize risk through precision dosing and cycle planning.